Your session is about to expire
← Back to Search
Liposomal Therapy
Ceramide NanoLiposome for Acute Myeloid Leukemia (KNAN2001 Trial)
Phase 1
Waitlist Available
Research Sponsored by Keystone Nano, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Refractory AML: Patients who fail to achieve a complete remission (CR) after one line of AML directed therapy.
Relapsed AML: Patients who achieved a complete remission (CR) with one or more prior lines of AML directed therapy but then developed a relapse of AML.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 24 weeks, and up to 24 weeks afterwards (total of 48 weeks)
Awards & highlights
KNAN2001 Trial Summary
This trial tests if combining a new drug with existing cancer treatments can make them more effective.
Who is the study for?
This trial is for adults over 18 with Acute Myeloid Leukemia (AML) that didn't respond to initial treatment or came back after. They should be in fairly good health otherwise, able to follow the study plan, and not have had a stem cell transplant recently or other cancers within the last year.Check my eligibility
What is being tested?
The trial tests Ceramide NanoLiposome (Ceraxa), which might boost the effectiveness of standard cancer drugs against AML. Participants will receive CNL combined with conventional treatments to see if this improves outcomes.See study design
What are the potential side effects?
While specific side effects of CNL are not listed here, common ones from similar cancer therapies include nausea, fatigue, increased risk of infection due to low blood counts, liver issues, and potential heart problems.
KNAN2001 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My AML did not respond to the first treatment.
Select...
My AML cancer returned after treatment.
Select...
I am 18 or older with AML that has not responded to treatment or has come back.
Select...
I can take care of myself and am up and about more than half of my waking hours.
KNAN2001 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 24 weeks, and up to 24 weeks afterwards (total of 48 weeks)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 24 weeks, and up to 24 weeks afterwards (total of 48 weeks)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Clinical Response - Complete Response
Clinical Response - Complete Response with Incomplete Hematologic Recovery (CRi)
Clinical Response - Partial Remission
+11 moreSecondary outcome measures
Event Free Survival
Number of Patients with Grade 3 or 4 Adverse Events
Overall Response
+2 moreKNAN2001 Trial Design
1Treatment groups
Experimental Treatment
Group I: Open Label Administration of Ceramide NanoLiposomeExperimental Treatment1 Intervention
Ceramide NanoLiposome will be administered by Intravenous Dosing twice per week in accordance with the protocol relative to dose escalation. There is no placebo group or arm of the study.
Find a Location
Who is running the clinical trial?
Keystone Nano, IncLead Sponsor
1 Previous Clinical Trials
24 Total Patients Enrolled
University of VirginiaOTHER
753 Previous Clinical Trials
1,245,013 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterOTHER
1,933 Previous Clinical Trials
585,604 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger